AMGEN INC

AMGN Nasdaq CIK: 0000318154

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320
Mailing Address ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320
Phone (805)447-1000
Fiscal Year End 1231
EIN 953540776

Financial Overview

FY2025

$91.84B
Total Assets
$14.33
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report February 13, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
8-K Current report of material events February 3, 2026 View on SEC
8-K Current report of material events January 30, 2026 View on SEC
4 Insider stock transaction report November 21, 2025 View on SEC
4 Insider stock transaction report November 13, 2025 View on SEC
4 Insider stock transaction report November 13, 2025 View on SEC
4 Insider stock transaction report November 12, 2025 View on SEC
4 Insider stock transaction report November 12, 2025 View on SEC
4 Insider stock transaction report November 12, 2025 View on SEC

Annual Reports

10-K February 13, 2026
  • Amgen delivered a robust performance in 2025 with significant financial gains, including 10.4% revenue growth and 15.8% net income growth.
  • The successful integration of Horizon Therapeutics contributed $4.0 billion to total revenue, alongside strong organic growth from established products.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.